Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MCV-5 in Healthy Adults
NCT02810340Phase 1Completed
- Sponsor
- PATH
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Non-Adjuvanted MCV-5 in meningococcal meningitis (3 arms), sponsored by PATH. Primary endpoints: Number and Percentage of Participants Experiencing Solicited Events at 7 days, Number and Percentage of Subjects Experiencing Unsolicited Adverse Events, by Severity at 28 days and 1 more. Started Aug 2016; status: completed.
02
Drugs
Non-Adjuvanted MCV-5
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT02810340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810340.